Search

Displaying results 2361 - 2370 of 9667 in total
  1. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    [A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744] … [A245854] B-cell maturation antigen (BCMA) is a transmembrane glycoprotein member of the tumor necrosis factor receptor superfamily 17 (TNFRSF17) which is used as a biomarker for multiple myeloma.

    Synonyms: Autologous bi-epitope BCMA-targeted CAR T-cells
  2. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    -, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. … This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791]

  3. Drug

    Arformoterol

    go.drugbank.com/drugs/DB01274
    Approved

    It works by relaxing muscles in the airways to improve breathing. … The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients

  4. Drug

    Ferric pyrophosphate

    go.drugbank.com/drugs/DB09147
    ApprovedInvestigational

    Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. … [A31979] It presents an increasing interest as this insoluble form can be milder in the gastrointestinal tract and present higher bioavailability.[L1433]

  5. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. … novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine.

  6. Drug

    Anthoxanthum odoratum pollen

    go.drugbank.com/drugs/DB10404
    Approved

    Anthoxanthum odoratum pollen is the pollen of the Anthoxanthum odoratum plant. Anthoxanthum odoratum pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  7. Drug

    Brilliant blue G

    go.drugbank.com/drugs/DB15594
    Approved

    It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … [A188841,A188844] This membrane is thin and translucent, making it difficult to identify during eye surgeries that require high levels of visual accuracy.

  8. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with … It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.

  9. Drug

    Malathion

    go.drugbank.com/drugs/DB00772
    Approved

    Malathion is an irreversible cholinesterase inhibitor and has low human toxicity. … Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice.

  10. Drug

    Cresol

    go.drugbank.com/drugs/DB11143
    Approved

    At concentrations normally found in the environment however, cresols do not pose any significant risk for the general population.